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Abstract
The overall quality of care for musculoskeletal pain conditions is suboptimal, partly due to a considerable evidence-practice gap. In
osteoarthritis and low back pain, structured models of care exist to help overcome that challenge. In osteoarthritis, focus is on
stepped care models, where treatment decisions are guided by response to treatment, and increasingly comprehensive
interventions are only offered to people with inadequate response to more simple care. In low back pain, the most widely known
approach is based on risk stratification, where patients with higher predicted risk of poor outcome are offered more comprehensive
care. For both conditions, the recommended interventions and models of care share many commonalities and there is no evidence
that onemodel of care is more effective than the other. Limitations of existing models of care include a lack of integrated information
on social factors, comorbid conditions, and previous treatment experience, and they do not support an interplay between health
care, self-management, and community-based activities. Moving forwards, a common model across musculoskeletal conditions
seems realistic, which points to an opportunity for reducing the complexity of implementation. We foresee this development will use
big data sources and machine-learning methods to combine stepped and risk-stratified care and to integrate self-management
support and patient-centred care to a greater extent in future models of care.
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1. Background
Musculoskeletal pain conditions are the largest causes of
disability worldwide.30 Among the most disabling are knee and
hip osteoarthritis (OA) and low back pain (LBP), which affect
approximately 303 and 577 million people, respectively, resulting
in very large annual societal costs.30,35,86 An important contrib-
utor to these costs is poor-quality health care, including the
application of non–evidence-based treatments. Examples of this
are the overuse of imaging, surgery, and opioids, in circum-
stances when this is not aligned with current evidence-based
recommendations for first-line care.8,12,27,98,99
This suboptimal quality of care is in part due to the poor
implementation of evidence-based guidelines for both OA and
LBP.24,27,32,37,62,88,94 Bridging this evidence gap to provide
effective and affordable health care while ceasing the use of
harmful, non–guideline-adherent practices is a major chal-
lenge.12,24,27,31 However, it has great potential to significantly
improve health and reduce costs.12,26
Models of care that support best practice clinical decision-
making are potentially very useful for implementing guideline-
recommended care options (Table 1 for definitions of key
terms).10,25 In OA and LBP, stepped care and stratified care
models have been suggested to support decisions about care.
With stepped care, all patients are initially offered the same basic
care, and subsequent treatment efforts are only increased if
patients have not benefited sufficiently. An example of a stepped
care model is the “Beating Osteoarthritis” (BART) model.95
Similarly, the “Good Life with osteoArthritis in Denmark (GLA:
D)” program is considered the initial level in a stepped approach92
(Appendix A: Summary of example models; available as
supplemental digital content at http://links.lww.com/PR9/A76).
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In a risk-stratified care model, treatment is targeted to patient
subgroups when patients initially seek care, with more compre-
hensive care offered to patients at risk of poor outcomes. The
most widely known example of this approach is the STarT Back
Screening Tool with treatments matched to risk profiles of people
with LBP.44,96
To engage with the international challenges around improving
the management of musculoskeletal health conditions, there is a
need for models of care that can be widely implemented. With
recent reviews highlighting several similarities between recom-
mended treatment options and clinical practice guidelines for OA,
LBP, and other musculoskeletal conditions, it seems that similar
models of care might also be appropriate, which would reduce
the complexity of implementation.5,58 Exploring the general-
isability of models of care across conditions would inform
clinicians, researchers, and decision-makers about ways of
developing models of care and may facilitate implementation in
clinical practice.
Therefore, the aim of this overview was to examine the
conceptual similarities and differences between stepped care
and risk-stratified care, discuss lessons learned from work on
thesemodels, and describe possible future directions for the field.
2. Key message #1: models of care for osteoarthritis
and low back pain share many similarities
Multiple national and international guidelines exist for the care and
management of OA and LBP.58 These clinical guidelines typically
offer a series of recommendations for clinical procedures and
treatments with some offering explicit or implicit recommenda-
tions about models of care including stratified care models,
stepped care models, and hybrids of the 2. For example, the
NICE guidelines from the United Kingdom explicitly recommend
risk-stratified care for LBP,68 whereas the OARSI guidelines for
knee and hip OA recommend a stepped care approach including
a core initial treatment for all patients consisting of education and
exercise with or without weight management.8 Furthermore, the
OARSI guidelines advocate elements of stratified care by
differentiating care for people with and without comorbidities.
Examples of guidelines that implicitly recommend stepped
care are the recommendations for OA and LBP management
stating that surgery is only considered for specific groups of
patients and only if nonsurgical care of a sufficient dose has
already been provided without adequate symptom relief.8,58,73
Another example is the recommendation that pharmacological
treatment is only initiated for chronic LBP in patients who had
inadequate response to nonpharmacological therapy.79
In OA, stepped care is themost commonly advocatedmodel of
care, whereas in LBP hybrid models, elements of both stepped
and risk-stratified care are included in clinical guidelines.8,73 Both
models have basic treatments (recommended for everybody with
the condition), adjunct treatments (for some), and surgical
options (for a minority).8,44,73 Despite some differences in models
of care, many aspects of treatment essentially remain the same.
For example, self-management advice and education are in-
cluded for all patients, and should be continuously delivered
throughout all steps of the treatment pathway.8,68,73
Exercise therapy is also a core element in the treatment of both
OA and LBP due to its therapeutic effects in these conditions, the
concurrent benefits of physical activity for common comorbidities
and general health, and because it is a safe treatment
option.9,75,80,91 Examples in OA are the Enabling Self-
management and Coping with Arthritis Knee Pain through
Exercise (ESCAPE-knee pain) and Beating Osteoarthritis (BART)
programs in the United Kingdom, the PARTNER model in
Australia, and GLA:D for knee and hip offered in several countries
in the world.3,47,48,84,92 These are all stepped care models that
include supervised exercises as part of the treatment, either for all
patients (ESCAPE, PARTNER, and GLA:D) or where self-
management advice has proven insufficient (BART). In LBP,
most clinical guidelines do not recommend supervised exercises
for acute LBP, but consistently do so for persistent LBP.4,73
Following the stratified care principle, the NICE guidelines
recommend that the decision about exercise therapy is guided
by the STarT Back model for LBP with supervised exercises
provided for people at medium risk and high risk of having
persistent activity limitation after 6 months, irrespective of
episode duration.68
Adjunct and more intensive treatments, such as psychologi-
cally informed physiotherapy using a combined physical and
psychological approach, are perhaps where the greatest
differences between OA and LBP models are presently seen.
Some LBP guidelines stress the importance of early identification
of those at high risk of poor clinical outcome due to psychosocial
obstacles to recovery in order that they are fast-tracked to
therapists who can address these issues,68 whereas OA
guidelines have until recently only included psychological
treatments to a lesser extent.67 However, recent OA guidelines
have recommended addressing psychological factors in certain
patient subgroups and are, in this aspect, suggesting a stratified
approach.8 Also, return-to-work interventions are recommended
without delay in both OA and LBP for subgroups who are
struggling with their capacity to work or have been absent from
work. Differences in treatment recommendations include that
weight loss, orthoses, and corticosteroid injections can play a role
in the treatment of OA, whereas that is not the case in LBP. Best
practice for painmedication also differs to some extent for OA and
LBP, with stepped models in OA suggesting different tiers of
medication be tried in a stepped fashion, whereas in LBP, the role
Table 1
Definitions of key terms as used in this article.
Term Definition
Clinical guidelines Recommendations for clinical practice informed by
systematic reviews of evidence and expert opinion,
including an assessment of the benefits and harms
of alternative care options.
Model of care Framework that describes the principles of disease‐
specific, evidence‐informed health care that should
be delivered to consumers in a given setting, that is,
the right care, at the right time, delivered by the
right team, in the right place, using the right
resources10
Moderator A factor (or combination of factors) that affects the
direction and/or strength of the relationship
between the exposure (eg, treatment) and the
outcome. For example, a factor that affects the
response to a treatment.
Prediction model/tool A model/tool consisting of factors that in
combination help predict the likely outcome of an
individual with a given intervention
Treatment decision tool A tool consisting of factors that in combination helps
predict the likely effect of one treatment compared
with another treatment
Risk stratification tool A tool that combines a prediction model (of risk of
poor outcome) with treatment options for each risk
stratum
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of pain medication is being questioned because of lack of effect
and risk of harm.87
Finally, decision-making about referral for surgical opinion is
similar for OA and LBP in the sense that surgery is only
considered if best-practice nonsurgical treatments have not
provided sufficiently good outcomes. However, currently, there is
a lack of evidence for surgical treatment as an effective option in
nonspecific LBP.27,73,97
In summary, clinical guidelines for both OA and LBP
recommend elements of stepped care and stratified caremodels,
including some explicit recommendations of stepped care in OA
and stratified care in LBP. Although the same core treatments are
recommended for patients with OA and LBP, some differences
emerge in the clinical decision-making process around some
adjunct therapies.
3. Key message #2: it is not a choice between
stepped care or stratified care—rather, it is about
using the best from both of them
A fundamental difference between these 2 models of care is that
stepped care assumes a substantial number of patients will
improve with core treatment, and patients who do not are not
harmed by waiting for more comprehensive treatment to be
initiated.59 By contrast, risk-stratified care assumes that patients
with poor outcomes can be identified at an early point of care-
seeking and their risk of poor outcomes reduced by early targeted
interventions.45,59
The risk of overtreatment and undertreatment with stepped
care clearly depends on the content of care at each step. If the
initial step only includes, eg, self-management advice, more
people are potentially being undertreated with a stepped
approach than by risk stratification. By contrast, where more
comprehensive core treatment packages are the initial level of
care (eg, including pain medication), there is a risk of over-
treatment and adverse events in patients who would improve
sufficiently with self-management advice alone. The likelihood
that patients are overtreated or undertreated with risk-stratified
care depends on the accuracy with which patients benefitting
from more intensive care can be identified.33,51 In addition to an
accurate screening tool, better outcomes rely on there being
suitably effective treatment options available for each risk
stratum. Both models of care guide which general approach to
follow, with room for clinical judgement and individualisation of
care that directs treatment at patients’ individual prognostic
factors, impairments, and treatment preferences.
Despite differences, the fundamental approach that informs
both of these models is that treatment choice differs between
patients based on individual patient information. In stepped care,
this information is the response to prior treatment and in risk-
stratified care, it is information on prognostic factors (the
predicted outcome).36,72 Consequently, patients seeking care
for the first time with an estimated good prognosis will have the
same treatment with stepped or stratified care. This may also
apply to patients seeking care early after symptomonset because
there is greater uncertainty with prediction in the acute stage.63
To the best of our knowledge, no trials have directly compared
the effectiveness of different models of care in musculoskeletal
conditions. Stratified care for LBP based on the STarT Back
Screening Tool was cost-effective when compared with usual
care (no specifiedmodel of care) in a U.K. effectiveness trial and in
an implementation study, with usual care being determined by
the individualised treatment decisions made by general practi-
tioners.28,44 In an Irish nonrandomised controlled study,
improved outcomes were observed for high-risk patients with
risk stratification, seemingly without affecting outcomes for low-
risk and medium-risk patients.66 Also, an implementation
strategy, including the use of the STarT Back Screening Tool in
Danish general practice, led to lower rates of referral to hospital
settings.83 However, the implementation of the STarT model was
not as successful in a U.S. study,15 illustrating that effective
implementation strategies for models of care may vary across
different international health service contexts. The effectiveness
of a stepped care model for other musculoskeletal conditions has
not been investigated using a controlled design. However, a
randomised controlled trial in knee OA has demonstrated that a
substantial proportion of patients considered eligible for surgery
achieved satisfactory outcomes with alternative nonsurgical
treatment and decided not to proceed with surgery.93 This
implied that the stepped approach of offering core nonsurgical
treatments before considering surgery is an effective strategy for
some patients.
Currently, there are a number of trials investigating the
effectiveness of risk-stratified care for LBP in different settings
and countries,13,38,64 and trials are being conducted to test
stepped care approaches in OA2 and LBP81 (examples were
identified from ClinicalTrials.gov). Also, we identified one pub-
lished pilot study and protocol for a trial testing stratified care in
musculoskeletal conditions including OA.39,40 No trials or
protocols were identified on head-to-head comparisons of
stepped and stratified models of care. Although there is limited
research to inform whether models of care could be the same for
OA and LBP or if one model should be chosen rather than the
other, a recent focus group study indicated that practitioners
consider a generic stratified model to be relevant across 5
musculoskeletal conditions.78
Given the similarities and overlapping practical applications of
stepped and risk-stratified care, these models may be consid-
ered parts of a common approach with elements of each model
being present at different time points in decision-making (Fig. 1).
As described in key message #1, such a combined approach is
implicitly advocated by current clinical guidelines. A stepped
approach is used in the very early stage of symptoms, where all
patients are offered basic care supporting self-manage-
ment.2,20,97 From primary care settings, which mostly managed
nonacute LBP presentations, there is evidence that risk
stratification can be cost-effective as a tool for making decisions
about care pathways. The precise content of treatment is to some
extent individualised within both stepped and stratified care. For
example, in the GLA:D programs for knee, hip, and back pain and
the ESCAPE-knee pain intervention, there is individualisation of
exercise programs by adaptation of type and dose to the
individual patient.48,92 Similarly, in LBP, patients who are stratified
to the same level according to the STarT Back Screening Tool
have different treatments tailored to their individual risk fac-
tors.36,92 In both OA and LBP, decisions about surgical care
follow a stepped approach based on observed response to
nonsurgical care (except for very special cases of trauma or
progressive neurological deficits).8,50 At the level of surgical
assessments, risk stratification again has a role, which may mean
that people with a high risk of poor outcome from surgery would
not be recommended this treatment or are perhaps offered more
intensive rehabilitation (Fig. 1). However, although there are
known risk factors for poor outcome with surgery, currently there
are no well-established decision support tools for surgery or other
secondary care settings. There is a model for predicting outcome
of total knee arthroplasty albeit with only partial support for its
external validity.21,82 Also, a decision support tool for spinal fusion
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surgery is being developed,85 but there is no evidence yet that
implementation of risk stratification on the basis of these 2
approaches does actually improve patient outcomes. There is
evidence that the STarT Back Screening Tool, which was
developed for primary care, is not useful for predicting outcomes
in secondary care settings,52,65 but stratified care for LBP
(matched treatment to risk profiles) has not been investigated in
secondary care settings. Also, at this point, there is no evidence
to inform exactly how models of care might most optimally be
combined.
Although musculoskeletal conditions are very often recur-
rent,18,19,71,74 and many people with OA and LBP seek care
repeatedly with periods of self-management in between, none of
the existing models explicitly suggest how recurrence is handled.
Episodic pain generally has less negative impact than persistent
pain and recurrences do not necessarily indicate progression of
the condition.55 Therefore, recurrences should not automatically
lead to more intensive care, and treatment decisions should
rationally take previous treatment response and success with
self-management into account.
4. Key message #3: risk stratification has different
roles and implications depending on how, when, and
where it is applied
In general, within risk stratification tools, there are 2 different types
of prognostic factors: those that are treatment-modifiable (eg,
pain, fear, and pain catastrophising) and those that cannot be
modified with treatment (eg, number of previous recurrences,
age, and previous surgery). This distinction becomes important
when designing prognostic tools and prediction models because
both types of prognostic factors have different roles and
implications for clinical practice. The inclusion of treatment
modifiable factors has the benefit that it gives clinicians some
signals about potential treatment targets. By contrast, non-
modifiable factors, although they do offer useful prognostic
information, are not helpful for identifying the specific target of
treatments but could have the advantage, by their very nature, of
being more stable than modifiable factors in their predictive
abilities across different settings. An example to illustrate that
prediction bymodifiable factors can be unstable is the finding that
the STarT Back Screening Tool (which only includes modifiable
factors) had poor predictive performance in emergency care61
and among patients with a very short LBP duration (,2 weeks) in
primary care.63 In both settings, this could be because many of
the factors screened (eg, catastrophising, anxiety, and fear) are
not sufficiently stable in very acute patients to be reliable
prognostic indicators in these situations. The inclusion of some
nonmodifiable factors in a predictive tool designed for the fast-
changing emergency context is, therefore, being planned as a
possible way of adding greater predictive stability to risk tools in
this setting. Prognostic factors that are not modifiable by
treatment, eg, socioeconomic status, also play an important role
in identifying people unlikely to benefit from standard interven-
tions, who should be offered support that takes their life
circumstances into account.22
Another important issue for the development and application of
prognostic models as part of decision-making is the need to be
clear about the exact outcome the model is designed to predict
and the exact purpose of using themodel. In principle, there are 3
different purposes of prediction in models of care: (1) Estimating
prognosis with a given treatment or in a given setting regardless of
potential treatment differences (what is the likely outcome of this
patient with this treatment/in this setting?); (2) Informing the
extent/intensity of care (which care pathway is best for this patient
considering both benefits and harms?); and (3) Informing the type
of treatment (which treatment is most effective for this patient?)
(Table 2).
Those distinctions are important because the research
methods used to develop and validate different types of models
are completely different. Tools meant to predict outcome in a
given setting are based on prognostic models developed using
observational cohort data, whereas tools designed to inform
decisions about care pathways or treatments typically require
Figure 1. Principles of combining stepped and stratified models of care. Existingmodels of care coexist in musculoskeletal care to form a joint model with stepped
and stratified approaches to making treatment decisions being used at different points along the clinical course. The figure illustrates principles and some parts of
this combined model remain to be investigated.
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moderators of treatment effect to be identified using data from
randomised clinical trials.42 An alternative method is to conduct a
randomised controlled trial to compare the combined effect of
using a prognostic model developed from a cohort study and
matched care pathways/interventions against another approach
(eg, usual nonstratified care). However, this has some limitations
because it is not able to confirm (without the trial being powered
to test for a treatment interaction effect) whether the matched
treatments used are indeed moderators of treatment effect. All
types of prognostic models need external validation and the
testing of clinical implications of using the tool before
implementation.16
The subtle but important differences between types of
prognostic models are the source of much confusion, particularly
because the clinical implications from the types of tools are very
different. In the case of a prediction tool designed to predict a
patient’s likely response to a specific treatment, patients who are
classified as “high risk” means they are at high risk of treatment
failure, and so the clinical implication is to avoid giving that patient
that specific treatment. However, with risk stratification tools, there
are different treatment options suggested for each of the risk strata
(subgroups at increasing risk of poor outcome), and patients who
are classified as “high risk” in this context typically receive a greater
intensity of treatment and/or more complex treatment. It is
therefore easy to see why clinicians are often confused by the
term “high risk” because the term means very different things
depending on the type of predictive tool being applied.
Finally, as mentioned under key message #2, there is a need to
consider a person’s long-term history and previous episodeswhen
models of care are applied, which existing risk stratification tools
currently do notmeasure. For example, patientsmight be classified
as being at a “low risk” of persistent disability, but they are actually
troubled by repeated episodes that cumulatively have a consider-
able impact on their life. To overcome this issue, we anticipate that
future risk stratification tools will likely need to include trajectory
information to better inform a longer-term, rather than short-term,
treatment perspective. For example, theymight include information
from the validated self-reported Visual Trajectories Questionnaire
(VTQ-Pain) that asks patients to choose from 8 picture diagrams to
identify their longer-term pain experience,23 or use automated
searches of electronic medical record data to capture an
individual’s medical history and treatment experience.
5. Key message #4: future directions
In the future, models of care for OA and LBP are likely to include:
(1) greater precision of risk assessment and individualised
treatment through better technologies, (2) greater patient agency
through self-care/community-based care and digital health
awareness, and (3) more advanced training of primary care
clinicians to use digital health tools and to engage in the
psychosocial aspects of musculoskeletal conditions.
5.1. Better technology
Advances in technology have the potential to integrate stratified,
stepped, and individualised care with the common aim of
identifying the “the right treatment for the right patient at the right
time.” One aspect of this is the development of dynamic prediction
models based onmachine learning (artificial intelligence) instead of
developing a single prediction model based on a sample of the
population at a single point in time. Such models are dynamically
updated in response to new people entering the sample,
prognostic variables being refined over time, and changes in
prognosis due to the setting, or advances in treatments and
models of care.49 Another advantage is the capacity to update
prognostic estimates for individuals over time by using clinical
course data as they emerge, thereby better mimicking clinical
reasoning than traditional approaches to prediction modelling.100
So, dynamically updated models have the capacity to include
elements of both stepped care (based on response to care) and
stratified care (based on prognostic factors).
Other technical advances are the integration of synergistic
technologies to improve models by the inclusion of data from
multiple sources, such as large (big data) clinical databases,
wearable sensors, and mobile device apps. The Back-Up
Table 2
Purposes and principles of prognostic models in decision-making.
Purpose Example* (level of evaluation) Principle Effectiveness testing Proposed term
To inform expected prognosis,
given a specific treatment or care
pathway
“What is the likely outcome of this
patient with this treatment/in this
setting?”
Predicting number of days to recovery
(pain #1 on a 0–10 scale) in people
with acute LBP visiting primary care
“The Hancock model” (externally
validated; no test of impact)17,34,101
Patients predicted to have a good
outcome have minimal intervention,
with more attention paid to those
predicted to have poor outcome. No
recommended matched treatments
detailed and the influence of care on
the outcome is not considered.
Effectiveness is tested in studies
investigating if use of the prediction
model affects, eg, patient outcomes,
care pathways, or costs.
This may be in a “subgroup system
RCT”53
Prediction model/
rule/tool
To guide which care pathway to
take/level of care to provide
“Which care pathway is best for
this patient?”
Determining care pathway based on
predicted risk of activity limitation
after 6 months at the initial point of
care-seeking.
“The STarT back screening tool”
(externally validated effectiveness
trial, impact study, mediation
analyses to confirm treatment
targets)28,41,44,60
Patients in subgroups at increased
risk of poor prognosis are offered
more comprehensive care.
Recommended matched treatments
for risk subgroups are based on
expert opinion.
Effectiveness is tested in trials
comparing the risk-stratified model of
care to usual nonstratified care or an
alternative model of care.
This is referred to as a “subgroup
system RCT”53
Stratified care tool
To guide whether to provide a
specific type of treatment
“Which treatment is likely to be
most effective for this patient?”
Deciding treatment choice based on
predicted outcome with one specific
treatment compared with another
treatment (no validated examples
from OA or LBP)
Patients positive on factors
associated with better outcome with
treatment A than with treatment B
(“treatment effect moderators”) are
offered treatment A.
Treatment decision tools are both
designed and tested in a “2-group
plus subgroup RCT”53
Treatment decision
rule/tool
* Examples of the purpose. There is no evidence of effectiveness/clinical impact of all types.
LBP, low back pain; OA, osteoarthritis; RCT, randomised controlled trial.
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Project7 and the Self-Back Project89 are examples of projects that
integrate these technologies in clinical decision tools for LBP in
first-contact settings and ongoing care settings and also for self-
management. An example of using information from wearable
sensors is the use of real-time feedback on back position and
movement in the treatment of LBP.54
The use of these technologies has the potential to facilitate the
regular follow-up andmonitoring of chronic health conditions, such
as kneeOAandLBP,where self-management includingexercise is
a core component. However, barriers exist to the development of
these integrated technology approaches, including cost, clinician
time constraints and cultural resistance, and concerns about the
privacy of patient data.6 As with any sociotechnical system, the
most successful approaches will require a combination of tangible
health benefits, timely and patient-enabling information, user-
friendly and accessible technology, and affordability.
More broadly, there is an emerging hybrid model of care with a
flexible mix of both face-to-face health care and digital health
solutions depending on the individual’s needs. Better technolo-
gies are increasingly providing enabling information during
assessment, diagnosis and treatment decision-making, and the
automation of components for monitoring patient progress.
5.2. Advanced training of primary care clinicians
In recognition of the multidimensionality of persistent musculo-
skeletal conditions,29 risk stratification and targeted care in-
creasingly traverse biopsychosocial factors. Because patient and
clinician cognitions and emotions about health conditions are
strongly prognostic,76 there is considerable research being
conducted into a range of targeted treatment approaches that
include screening for, and engagement with, these psychosocial
aspects when appropriate.90 However, there are a number of
challenges to be addressed, including primary care clinician time
constraints, clinician professional self-image and perceptions of
scope of practice,1,77 and a lack of clarity about the best models
of training, and for whom they are most appropriate.
As digital health technologies to assist diagnosis, support
treatment, report patient outcomes and experiences increasingly
merge and blend into comprehensive tools, this will have an impact
on clinician training needs. For example, new digital health
technologies are already being developed to support back pain
clinical decision-making, such as the Back-UP project,7 which is
digitising risk stratification and the monitoring of patient outcomes
during rehabilitation. It is also likely that existing clinical decision
support tools for OA, such as the Arthritis Alliance of Canada’s OA
Tool (https://www.cfpc.ca/uploadedFiles/CPD/OATOOL_FINAL_
Sept14_ENG.pdf), will be transferred from existing paper-based
formats into a digital health technology. It is likely that these types of
tools will increasingly be integrated into existing medical health
record and patient management systems and that process will
simultaneously require clinician training to understand how to best
make use of these technologies and the metrics they provide. We
expect this change to be driven by both the potential of these
technologies to facilitate improvements in the quality of care and by
their ability to help secure better informed funding of clinical services.
5.3. Greater patient agency
There is an increasing recognition of the merit of demedicalising
musculoskeletal care and shifting towardsmodels of care that are
more patient-centred and focused on supporting self-manage-
ment.12,57 There is also a shift away from defining health as
“complete well-being” to defining health as “an ability to adapt
and self-manage” and towards models of care that integrate
health care with self-care and community-based activities.46 For
example, although only a minority of people with OA regularly
engage in physical activity at recommended levels, a clinical trial
in Canada showed that both community-based and home-based
walking programs can be effective strategies to manage mild to
moderate OA of the knee.11 Quality of life and clinical outcomes
improved among participants across a 12-month intervention
period and continued to improve 6 months later.
The management of chronic conditions is increasingly about
supporting patients’ decisions as well as clinicians’ decisions,
which should be reflected in decision support tools for patients and
clinicians. Decision support tools aimed at patients will have to take
individual capacities, other health conditions, and social context
into account. Future models of care will also need to address the
social inequalities in health that are not necessarily captured by
illness-specific or modifiable risk factors.14 Greater patient agency
is also being promoted through trusted review websites (eg, www.
orcha.co.uk) that allow end-users to compare different digital
health products, such as patient apps and health websites.
The clinical utility of these 3 emerging and enabling directions
(greater precision through better technologies, greater patient
agency, and more advanced training of primary care clinicians)
will remain contingent on appropriate evaluations of benefits,
harms, costs, and their potential for implementation, for example,
using guidance from the Evidence Standards Framework for
Digital Health Technologies published by NICE.69
6. Discussion
Models of care provide a framework for implementing evidence into
practice and reducing the variation in care. At present, there is no
direct evidence that one particular care model is superior to
another, and the approaches of stepped and stratified care both
play a role in the organisation of interventions for OA and LBP. This
overview illustrated that the content of care and the overall
approach to treatment decisions sharemany similarities in bothOA
and LBP, and a common model of care emerged. In both OA and
LBP, all patients should receive information about their condition
and advice on self-management, and also supervised exercises
are part of core treatment in bothOAandpersistent LBP,with other
optional interventions for somepatients.Currently, risk stratification
is only applied in LBP, but whether effectiveness of care can be
improved by applying risk stratification in other musculoskeletal
conditions is also being investigated.43,70 Generally, the observed
differences in the models of care for OA and LBP are not
substantiated by evidence, and the potential for integrated models
across musculoskeletal conditions deserves attention.
In the development, testing, and implementation of models of
care, there are some potential pitfalls to be aware of. Importantly,
careful consideration should be given to whether a decision
support tool is meant for predicting outcome irrespective of
treatment (to decide the level of attention needed), for predicting
likely outcome given a specific treatment (to decide if that specific
intervention should be offered or not), or for predicting added
benefit from one treatment compared with another (to decide
which treatment to choose).
Limitations of current models include that they do not
sufficiently guide clinicians in integrating information about
patients’ symptom trajectory, nonmodifiable prognostic factors,
comorbid conditions, and previous treatment response, and they
do not support an interplay between health care, self-
management, and community-based activities. Also, the way in
which models of care might best be adapted to differences in the
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local health care contexts is still unknown. We foresee that future
models of care will use big data sources and machine-learning
methods to overcome some of these limitations. Even without the
use of new technologies, models of care for musculoskeletal
conditions need development to include existing knowledge of
symptom trajectories,56 and to integrate self-management
support and patient-centred care to a larger extent.8,12
In summary, existingmodels of care for OA and LBP showgood
potential for improving management of musculoskeletal health
care and they share many commonalities. This points to an
opportunity for reducing complexity of implementation of guideline-
recommended interventions by standardisation across health
conditions. Nonetheless, individual care decisions are complex,
and implementation strategies will differ across healthcare
contexts. We foresee that insights from existing and future
research will combine with new technologies to overcome
elements of this complexity with promise for better models of care.
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